Pharma Equity Group A/S Cl A - Asset Resilience Ratio

Latest as of June 2019: 2.24%

Pharma Equity Group A/S Cl A (PEG) has an Asset Resilience Ratio of 2.24% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read total liabilities of Pharma Equity Group A/S Cl A for a breakdown of total debt and financial obligations.

Liquid Assets

Dkr1.72 Million

≈ $269.58K USD Cash + Short-term Investments

Total Assets

Dkr77.09 Million

≈ $12.06 Million USD All company assets

Resilience Assessment

Low

Financial Resilience Level

Asset Resilience Ratio Trend (2008–2018)

This chart shows how Pharma Equity Group A/S Cl A's Asset Resilience Ratio has changed over time. See PEG net assets for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Pharma Equity Group A/S Cl A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Pharma Equity Group A/S Cl A.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	Dkr0.00	0%
Short-term Investments	Dkr1.72 Million	2.24%
Total Liquid Assets	Dkr1.72 Million	2.24%

Asset Resilience Insights

Limited Liquidity: Pharma Equity Group A/S Cl A maintains only 2.24% of assets in liquid form.
This low level may indicate efficient asset utilization but could pose risks during economic downturns.
The company has significant short-term investments, indicating active treasury management.

Pharma Equity Group A/S Cl A Industry Peers by Asset Resilience Ratio

Compare Pharma Equity Group A/S Cl A's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
Sagimet Biosciences Inc. Series A Common Stock NASDAQ:SGMT	Biotechnology	63.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Beijing Tiantan Biological Products Corp Ltd SHG:600161	Biotechnology	8.08%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	43.36%
Inner Mongolia Furui Med Sci SHE:300049	Biotechnology	2.34%
Bio-Thera Solutions Ltd SHG:688177	Biotechnology	4.09%
Wuhan Keqian Biology Co Ltd SHG:688526	Biotechnology	19.42%
Gubra A/S CO:GUBRA	Biotechnology	79.61%

Annual Asset Resilience Ratio for Pharma Equity Group A/S Cl A (2008–2018)

The table below shows the annual Asset Resilience Ratio data for Pharma Equity Group A/S Cl A.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2018-09-30	2.13%	Dkr1.72 Million ≈ $269.58K	Dkr80.84 Million ≈ $12.65 Million	+1.06pp
2016-09-30	1.07%	Dkr1.35 Million ≈ $210.90K	Dkr125.75 Million ≈ $19.67 Million	-0.27pp
2015-09-30	1.34%	Dkr1.69 Million ≈ $264.10K	Dkr126.25 Million ≈ $19.75 Million	-5.61pp
2012-09-30	6.95%	Dkr35.00 Million ≈ $5.48 Million	Dkr503.85 Million ≈ $78.83 Million	+0.05pp
2011-09-30	6.89%	Dkr35.00 Million ≈ $5.48 Million	Dkr507.76 Million ≈ $79.44 Million	-69.48pp
2008-09-30	76.37%	Dkr199.84 Million ≈ $31.27 Million	Dkr261.67 Million ≈ $40.94 Million	--

pp = percentage points

About Pharma Equity Group A/S Cl A

CO:PEG Denmark Biotechnology

Market Cap

$15.17 Million

Dkr96.98 Million DKK

Market Cap Rank

#25958 Global

#118 in Denmark

Share Price

Dkr0.08

Change (1 day)

+1.80%

52-Week Range

Dkr0.07 - Dkr0.15

All Time High

Dkr2.81